Screener
Beam Therapeutics BEAM CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other long-term liabilities | 134 | (89) |
| Net cash provided by (used in) operating activities | (128,513) | (103,884) |
| Investing activities | ||
| Purchases of property and equipment | (2,232) | (3,065) |
| Purchases of marketable securities | (153,792) | (339,169) |
| Maturities of marketable securities | 181,293 | 217,145 |
| Net cash provided by (used in) investing activities | 25,269 | (125,089) |
| Financing activities |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's capex?
- Beam Therapeutics (BEAM) reported capex of $2.23M in Q1 2026.
- How has Beam Therapeutics's capex changed year-over-year?
- Beam Therapeutics's capex decreased by 27.2% year-over-year, from $3.07M to $2.23M.
- What is the long-term trend for Beam Therapeutics's capex?
- Over 4 years (2021 to 2025), Beam Therapeutics's capex has grown at a -24.8% compound annual growth rate (CAGR), from $46.81M to $14.95M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Beam Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude